BeiGene embarks on $330M biologics plant project in China

China's BeiGene, which is developing a portfolio of immuno-oncology drugs, has a deal to build a $330 million biologics plant to produce them.

China’s BeiGene, which is developing a portfolio of immuno-oncology drugs it expects will challenge those of Western drugmakers, has struck a deal with a Chinese development agency to build a biologics plant to manufacture them.

The Hong Kong-based company said today that a joint venture with the Guangzhou Development District will build the manufacturing facility in Guangzhou, Guangdong Province, China. The JV will invest a total of RMB2.2 billion ($330 million) in the project.

“It is our strategic priority to secure high-quality large-scale manufacturing capacity based on the increasing biologics opportunity we envision in China and global markets,” BeiGene co-founder John Oyler said in a statement.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The joint venture, BeiGene Biologics, will be funded with an investment of about $30 million from BeiGene HK and $150 million from the district’s Guangzhou GET Technology Development unit, which will make both a cash equity investment in the JV and a shareholder loan. The joint venture also plans to get a $150 million loan.

BeiGene has a PARP inhibitor under development that it expects will compete with AstraZeneca's Lynparza and those of several other drugmakers that have PARPs in late-stage development, including Tesaro and Pfizer's new buy Medivation.

In addition to the PARP, BeiGene has a PD-1 inhibitor, a BTK inhibitor and a BRAF inhibitor in development. Morgan Stanley analyst Matthew Harrison has said the portfolio could collectively drive more than $1 billion in sales in China alone.

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.